Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Antisoma and Abbott revise pemtumomab licensing agreement

Jan. 8, 2002

Therion Biologics' cancer vaccine enters phase I trial

Jan. 3, 2002

Positive phase I/II AlloMune results for end-stage lymphoma

Dec. 31, 2001

IL-12 gene therapy studied in Japan for inducing tumor immunity

Dec. 27, 2001

European MAA submitted for Onzar in the treatment of cutaneous T-cell lymphoma

Dec. 20, 2001

Humanized anti-HM1.24 MAb well tolerated in phase I trial in myeloma patients

Dec. 14, 2001

FDA approves Herceptin labeling changes to add survival data

Dec. 14, 2001

Excellent safety, evidence of activity for beta-alethine in immunocompetent lymphoma patients

Dec. 13, 2001

Early data from NHL patients treated with CpG-7909 indicate good safety, immunostimulatory effects

Dec. 13, 2001

Phase II trial of Avicine cancer vaccine shows survival benefit

Dec. 12, 2001

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...